ETR1 Antibody

What is ETR1 and why are antibodies developed against it?

ETR1 refers to two distinct targets in scientific research. First, it can refer to the mitochondrial trans-2-enoyl-CoA reductase (MECR) protein involved in fatty acid metabolism. This protein has a canonical amino acid length of 373 residues and a mass of 40.5 kilodaltons, with localization in the nucleus, mitochondria, and cytoplasm . Second, ETR1 may refer to endothelin A receptor (ETAR), a G-protein-coupled receptor that has been studied extensively in various disease contexts, particularly in cardiovascular conditions and COVID-19 .

Antibodies against ETR1/ETAR are developed primarily for detecting the presence and quantity of these proteins in biological samples, studying protein-protein interactions, and investigating their roles in disease pathogenesis. In clinical research settings, antibodies against receptors like ETAR have been implicated in autoimmune responses associated with COVID-19 .

What are the principal applications of ETR1 antibodies in research?

ETR1 antibodies are employed in multiple experimental applications with Western Blot and ELISA being the most common techniques . These antibodies enable:

• Quantification of ETR1/ETAR expression levels in different tissue types

• Investigation of protein-protein interactions involving ETR1/ETAR

• Examination of subcellular localization through immunocytochemistry

• Assessment of autoantibody presence in patient samples, particularly in disease states like COVID-19

• Validation of genetic manipulation (knockdown/overexpression) experiments

• Study of signaling pathways associated with ETR1/ETAR function

For instance, in COVID-19 research, anti-ETAR antibodies have been crucial in assessing autoimmune responses, with enzyme immunoassays being used to detect autoantibodies against ETAR in patient serum samples .

How should researchers select the appropriate ETR1 antibody for their experiments?

When selecting ETR1 antibodies, researchers should consider several critical factors:

• Target specificity: Determine whether you need antibodies against ETR1 (MECR) or ETAR, as these are distinct proteins with different functions and cellular locations.

• Application compatibility: Verify that the antibody has been validated for your specific application (WB, ELISA, IHC, etc.). Product documentation should provide information about recommended dilutions and protocols for each application .

• Species reactivity: Ensure the antibody recognizes your species of interest. Available antibodies may be specific to human, mouse, rat, Arabidopsis, or even bacterial ETR1 proteins .

• Epitope location: Consider whether the antibody targets an epitope that will be accessible in your experimental conditions, especially for applications involving fixed or denatured proteins.

• Validation data: Review existing validation data, including positive and negative controls, to confirm antibody specificity and sensitivity.

• Form and conjugation: Determine whether you need unconjugated antibodies or those conjugated to reporters (fluorescent dyes, enzymes, etc.) based on your detection method.

What are the recommended protocols for validating ETR1 antibody specificity?

Validation of ETR1 antibody specificity is crucial to ensure experimental rigor. A comprehensive validation approach should include:

• Western blotting with positive and negative controls:

  • Positive controls should show a band at the expected molecular weight (40.5 kDa for human ETR1/MECR)

  • Negative controls may include samples from knockout models or tissues known not to express the target

• Immunoprecipitation followed by mass spectrometry:

  • This confirms that the antibody specifically pulls down ETR1/ETAR and not other proteins

• Peptide competition assays:

  • Pre-incubation of the antibody with the immunizing peptide should abolish or significantly reduce signal

• Cross-reactivity testing:

  • Test against related proteins to ensure specificity

  • For ETAR antibodies, testing against other endothelin receptors is essential

• Knockdown/knockout validation:

  • Compare staining/signal between wild-type and ETR1/ETAR-depleted samples

Recent computational approaches have also been developed for inferring antibody specificity through high-throughput sequencing and downstream analysis, which can provide additional validation of antibody-target interactions .

What is the significance of ETAR antibodies in COVID-19 pathogenesis?

Recent research has revealed important connections between ETAR antibodies and COVID-19 pathogenesis:

Autoantibodies against G-protein-coupled receptors (GPCRs), including ETAR, have been found at significantly increased levels in hospitalized COVID-19 patients compared to controls . In a study published in 2023, researchers found that baseline ETAR antibody titers were significantly higher in COVID-19 patients (median 12; IQR, 9–16) compared to controls (7; IQR, 5–10) and mechanically ventilated controls (7; IQR, 4–10) (p<0.001) .

These findings suggest that autoantibodies against ETAR might be specifically induced during SARS-CoV-2 infection rather than being a general response to severe respiratory illness. This is supported by the observation that intubated COVID-19 patients had significantly increased ETAR titers compared to patients with ARDS due to other causes .

How are ETAR antibody titers measured in clinical research settings?

In clinical research settings, ETAR antibody titers are typically measured using specialized enzyme immunoassays (EIAs). The standardized methodology includes:

• Sample collection and processing:

  • Blood samples are collected from patients, typically within 72 hours of admission

  • Serum is separated and stored appropriately until analysis

• Enzyme immunoassay (EIA) execution:

  • CE-marked enzyme immunoassays developed at specialized laboratories (e.g., CellTrend GmbH) are used

  • Manufacturer's instructions are followed precisely for sample handling and assay conditions

• Cutoff determination:

  • For antibodies against ETAR, a concentration of 10 U/mL is typically considered the cutoff value

  • Titers between 10–17 U/mL are considered borderline

  • Titers >17 U/mL are considered positive

• Quality control:

  • Positive and negative controls are included in each assay run

  • Calibration curves are established according to manufacturer recommendations

• Data analysis:

  • Statistical analysis typically employs non-parametric tests (Mann-Whitney U, Kruskal-Wallis) due to the non-normal distribution of antibody titers

  • Results are presented as median with interquartile range (IQR)

This standardized approach allows for reliable measurement and comparison of ETAR antibody titers across different patient populations and research settings.

What clinical applications have been investigated for therapeutic ETR1 antibodies?

Therapeutic antibodies targeting ETR1-related molecules have been investigated in several clinical contexts, with notable examples including:

HGS-ETR1 (also known as TRM-1 or mapatumumab) is a fully human monoclonal antibody that acts as an agonist to TRAIL-R1 (DR4), which has been evaluated in clinical trials for cancer treatment. A Phase 2 multicenter study investigated its efficacy in 40 subjects with relapsed or refractory non-Hodgkin lymphoma (NHL) .

The antibody was administered at two dose levels (3 mg/kg or 10 mg/kg) every 21 days for up to 6 cycles. The primary endpoint was tumor response evaluated using International Working Group Criteria .

Results from this trial showed:

• 3 subjects (8%), all with follicular lymphoma, had clinical responses (1 complete response, 2 partial responses)

• 12/40 subjects (30%) had stable disease

• The remainder had progressive disease at first evaluation

• 8 subjects (7 with follicular lymphoma) remained on study without disease progression for >5 to >13 months

What methodological considerations are important when evaluating therapeutic ETR1 antibodies?

When evaluating therapeutic ETR1-related antibodies in clinical research, several methodological considerations are crucial:

• Patient selection and stratification:

  • Careful selection of patient populations based on biomarkers related to the antibody's target

  • Stratification by disease subtype, as responses may vary significantly (e.g., follicular vs. diffuse large B-cell lymphoma)

  • Consideration of prior treatment history (69% of patients in the HGS-ETR1 trial had received 3 or more prior regimens)

• Dosing regimen optimization:

  • Evaluation of different dose levels (e.g., 3 mg/kg vs. 10 mg/kg for HGS-ETR1)

  • Determination of optimal treatment interval (21 days in the referenced study)

  • Assessment of maximum tolerated cycles (up to 6 cycles in standard protocols, with extensions possible for responders)

• Response evaluation:

  • Use of standardized response criteria (International Working Group Criteria in lymphoma studies)

  • Confirmation of responses between 4-8 weeks after initial documentation

  • Long-term follow-up to assess durability of responses (>5 to >13 months in responding patients)

• Safety monitoring:

  • Comprehensive assessment of adverse events and tolerability

  • Evaluation of immune-related adverse events, which may be particularly relevant for therapeutic antibodies

• Biomarker analysis:

  • Correlation of response with target expression levels

  • Investigation of potential resistance mechanisms

How can computational approaches enhance ETR1 antibody specificity?

Recent advances in computational biology have enabled sophisticated approaches to antibody design that can be applied to ETR1 antibodies. These methods allow researchers to:

• Predict binding modes and epitopes:

  • Computational models can identify different binding modes, each associated with particular ligands

  • This approach helps disentangle binding modes even when associated with chemically similar ligands

• Design customized specificity profiles:

  • Computational models trained on phage display experimental data can predict novel antibody sequences with predefined binding profiles

  • These models enable the design of either highly specific antibodies (targeting a single ligand while excluding others) or cross-specific antibodies (interacting with several distinct ligands)

• Optimize antibody sequences:

  • By parameterizing energy functions associated with each binding mode, researchers can optimize antibody sequences to minimize or maximize binding to specific targets

  • This approach has been validated experimentally, confirming the model's ability to propose novel antibody sequences with customized specificity profiles

The implementation of these computational approaches typically involves:

• High-throughput sequencing of antibody libraries before and after selection

• Development of statistical models that capture the evolution of antibody populations across experiments

• Optimization of model parameters to predict the expected probability of variant selection

• Experimental validation of computationally designed antibodies

What experimental validation approaches confirm computational ETR1 antibody designs?

Validation of computationally designed ETR1 antibodies requires rigorous experimental testing to confirm predicted specificity profiles. A comprehensive validation approach includes:

• Binding assays with purified antigens:

  • Surface plasmon resonance (SPR) to measure binding kinetics and affinity

  • Enzyme-linked immunosorbent assay (ELISA) to assess specificity against target and non-target antigens

  • Competitive binding assays to evaluate displacement by known ligands

• Cell-based validation:

  • Flow cytometry with cells expressing various levels of target protein

  • Immunofluorescence microscopy to assess binding pattern and subcellular localization

  • Cell-based functional assays to evaluate biological effects

• Cross-reactivity testing:

  • Comprehensive panel testing against related and unrelated proteins

  • Testing against proteins from different species to assess evolutionary conservation of binding

• Validation in complex biological samples:

  • Immunoprecipitation followed by mass spectrometry to identify all binding partners

  • Validation in tissue samples to assess specificity in complex environments

• Comparison with existing antibodies:

  • Side-by-side comparison with commercially available antibodies

  • Benchmarking against gold standard reagents

This multi-faceted approach ensures that computationally designed antibodies meet the rigorous standards required for research applications and potential therapeutic development.

What are common challenges when using ETR1 antibodies in Western blot and ELISA?

Researchers often encounter several challenges when using ETR1 antibodies in Western blot and ELISA applications:

For Western blotting:

• Non-specific binding:

  • Problem: Multiple bands appear on Western blots

  • Solution: Optimize blocking conditions (try different blocking agents like 5% milk, 5% BSA, or commercial blockers); increase washing steps; adjust antibody dilution

• Weak or no signal:

  • Problem: Target band is faint or absent

  • Solution: Ensure adequate protein loading (40.5 kDa for human ETR1/MECR); optimize antibody concentration; increase exposure time; check sample preparation to prevent protein degradation

• Inconsistent results across experiments:

  • Problem: Variability in band intensity between experiments

  • Solution: Standardize protocols; use internal loading controls; prepare fresh reagents; ensure consistent transfer conditions

For ELISA:

• High background signal:

  • Problem: Elevated readings in negative controls

  • Solution: Optimize blocking conditions; increase washing steps; adjust antibody concentration; test different plate types

• Poor sensitivity:

  • Problem: Difficulty detecting low levels of target protein

  • Solution: Use more sensitive detection systems; optimize antibody pairs for sandwich ELISA; employ signal amplification methods

• Cross-reactivity with similar proteins:

  • Problem: False positive results due to antibody binding to related proteins

  • Solution: Validate antibody specificity with positive and negative controls; perform competitive binding assays with purified proteins

How can researchers optimize protocols for detecting ETAR autoantibodies in patient samples?

Detecting ETAR autoantibodies in patient samples requires careful optimization to ensure accurate and reproducible results:

• Sample collection and processing optimization:

  • Standardize collection timing (e.g., within 72 hours of hospital admission for COVID-19 studies)

  • Process samples consistently (centrifugation speed/time, storage temperature)

  • Consider potential interfering factors (medications, recent transfusions)

• Enzyme immunoassay (EIA) optimization:

  • Follow manufacturer's instructions precisely for CE-marked assays

  • Determine optimal sample dilution through titration experiments

  • Include appropriate positive and negative controls in each run

• Cutoff determination and validation:

  • Establish cutoff values based on manufacturer recommendations (e.g., 10 U/mL for ETAR antibodies)

  • Validate cutoffs with known positive and negative samples

  • Consider borderline ranges (e.g., 10–17 U/mL) to account for assay variability

• Statistical analysis considerations:

  • Use non-parametric tests for non-normally distributed antibody titers

  • Present results as median with interquartile range (IQR) rather than means

  • Consider multivariable analysis to correct for confounders (age, sex, medications)

• Longitudinal monitoring optimization:

  • Standardize sampling intervals (e.g., baseline and day 7 of admission)

  • Ensure consistent storage conditions between timepoints

  • Account for treatment effects (e.g., steroid use) in analysis

By implementing these optimization strategies, researchers can enhance the reliability and interpretability of ETAR autoantibody measurements in clinical studies.